Antibody-Antimicrobial Conjugates for Combating Antibiotic Resistance.
Adv Healthc Mater
; 12(1): e2202207, 2023 01.
Article
en En
| MEDLINE
| ID: mdl-36300640
ABSTRACT
As the development of new antibiotics lags far behind the emergence of drug-resistant bacteria, alternative strategies to resolve this dilemma are urgently required. Antibody-drug conjugate is a promising therapeutic platform to delivering cytotoxic payloads precisely to target cells for efficient disease treatment. Antibody-antimicrobial conjugates (AACs) have recently attracted considerable interest from researchers as they can target bacteria in the target sites and improve the effectiveness of drugs (i.e., reduced drug dosage and adverse effects), abating the upsurge of antimicrobial resistance. In this review, the selection and progress of three essential blocks that compose the AACs antibodies, antimicrobial payloads, and linkers are discussed. The commonly used conjugation strategies and the latest applications of AACs in recent years are also summarized. The challenges and opportunities of this booming technology are also discussed at the end of this review.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inmunoconjugados
/
Antineoplásicos
Idioma:
En
Revista:
Adv Healthc Mater
Año:
2023
Tipo del documento:
Article
País de afiliación:
China